Cargando…
Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia
The extent of the SARS-CoV-2 circulation and the COVID-19 epidemic in Tunisia three months after virus circulation was unknown. The aim of this study was to determine the extent of SARS-CoV-2 infection among household contacts of confirmed COVID-19 cases living in Hot spot areas of Great Tunis, Tuni...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297112/ https://www.ncbi.nlm.nih.gov/pubmed/37367185 http://dx.doi.org/10.3390/epidemiologia4020020 |
_version_ | 1785063806281449472 |
---|---|
author | Dhaouadi, Sonia Letaief, Hejer Hechaichi, Aicha Safer, Mouna Moussa, Rym Bouhali, Ridha Letaief, Fethi Abdelkader, Latifa Ben Salah, Hamida El Mili, Nawel Hammami, Mongi Talmoudi, Khouloud Souteyrand, Yves Nabeth, Pierre Kouni Chahed, Mohamed Bouafif ép Ben Alaya, Nissaf |
author_facet | Dhaouadi, Sonia Letaief, Hejer Hechaichi, Aicha Safer, Mouna Moussa, Rym Bouhali, Ridha Letaief, Fethi Abdelkader, Latifa Ben Salah, Hamida El Mili, Nawel Hammami, Mongi Talmoudi, Khouloud Souteyrand, Yves Nabeth, Pierre Kouni Chahed, Mohamed Bouafif ép Ben Alaya, Nissaf |
author_sort | Dhaouadi, Sonia |
collection | PubMed |
description | The extent of the SARS-CoV-2 circulation and the COVID-19 epidemic in Tunisia three months after virus circulation was unknown. The aim of this study was to determine the extent of SARS-CoV-2 infection among household contacts of confirmed COVID-19 cases living in Hot spot areas of Great Tunis, Tunisia by estimating the seroprevalence of antibodies anti SARS-CoV-2 and to identify factors associated to seroprevalence at the first stage of the pandemic in order to guide decision making and to constitute a baseline for further longitudinal analysis of protective immunity to SARS-CoV-2. The National Observatory of New and Emerging Diseases (ONMNE), Ministry of Health Tunisia (MoH), with the support of the Office of the World Health Organization Representative in Tunisia and the WHO Regional Office for the Eastern Mediterranean (EMRO)), conducted a household cross-sectional survey on April 2020 in Great Tunis (Tunis, Ariana, Manouba and Ben Arous). The study was based on the WHO seroepidemiological investigation protocol for SARS-CoV-2 infection. SARS-CoV-2 specific antibodies (IgG and IgM) were qualitatively detected using a lateral immunoassay that detect SARS-CoV-2 nucleocapsid protein and administered by the interviewers. The included subjects were confirmed COVID-19 cases and their households contacts resided in hot spot areas (cumulative incidence rate ≥ 10 cases/100,000 inhabitants) of Great Tunis. Results: In total, 1165 subjects were enrolled: 116 confirmed COVID-19 cases (43 active cases and 73 convalescents cases) and 1049 household contacts resided in 291 households. The median age of participants was 39.0 with 31 years’ interquartile range (Min = 8 months; Max = 96 years). The sex ratio (M/F) was 0.98. Twenty-nine per cent of participants resided in Tunis. The global crude seroprevalence among household contacts was 2.5% (26/1049); 95% CI 1.6–3.6%, 4.8%; 95% CI 2.3–8.7% in Ariana governorate and 0.3%; 95% CI 0.01%–1.8% in Manouba governorate. In multivariate analysis, the associated factors independently related to seroprevalence were age ≥25 years (aOR = 5.1; 95% CI 1.2–22.0), history of travel outside Tunisia since January 2020 (aOR = 4.6; 95% CI 1.7–12.9), symptomatic illness in the previous four months (aOR = 3.5; 95% CI 1.4–9.0) and governorate of residence (p = 0.02). The low seroprevalence estimated among household contacts in Great Tunis reflect the effect of public health measures early taken (national lockdown, borders closed, remote work), the respect of non-pharmaceutical interventions and the efficacy of COVID-19 contact-tracing and case management at the first stage of the pandemic in Tunisia. |
format | Online Article Text |
id | pubmed-10297112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102971122023-06-28 Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia Dhaouadi, Sonia Letaief, Hejer Hechaichi, Aicha Safer, Mouna Moussa, Rym Bouhali, Ridha Letaief, Fethi Abdelkader, Latifa Ben Salah, Hamida El Mili, Nawel Hammami, Mongi Talmoudi, Khouloud Souteyrand, Yves Nabeth, Pierre Kouni Chahed, Mohamed Bouafif ép Ben Alaya, Nissaf Epidemiologia (Basel) Article The extent of the SARS-CoV-2 circulation and the COVID-19 epidemic in Tunisia three months after virus circulation was unknown. The aim of this study was to determine the extent of SARS-CoV-2 infection among household contacts of confirmed COVID-19 cases living in Hot spot areas of Great Tunis, Tunisia by estimating the seroprevalence of antibodies anti SARS-CoV-2 and to identify factors associated to seroprevalence at the first stage of the pandemic in order to guide decision making and to constitute a baseline for further longitudinal analysis of protective immunity to SARS-CoV-2. The National Observatory of New and Emerging Diseases (ONMNE), Ministry of Health Tunisia (MoH), with the support of the Office of the World Health Organization Representative in Tunisia and the WHO Regional Office for the Eastern Mediterranean (EMRO)), conducted a household cross-sectional survey on April 2020 in Great Tunis (Tunis, Ariana, Manouba and Ben Arous). The study was based on the WHO seroepidemiological investigation protocol for SARS-CoV-2 infection. SARS-CoV-2 specific antibodies (IgG and IgM) were qualitatively detected using a lateral immunoassay that detect SARS-CoV-2 nucleocapsid protein and administered by the interviewers. The included subjects were confirmed COVID-19 cases and their households contacts resided in hot spot areas (cumulative incidence rate ≥ 10 cases/100,000 inhabitants) of Great Tunis. Results: In total, 1165 subjects were enrolled: 116 confirmed COVID-19 cases (43 active cases and 73 convalescents cases) and 1049 household contacts resided in 291 households. The median age of participants was 39.0 with 31 years’ interquartile range (Min = 8 months; Max = 96 years). The sex ratio (M/F) was 0.98. Twenty-nine per cent of participants resided in Tunis. The global crude seroprevalence among household contacts was 2.5% (26/1049); 95% CI 1.6–3.6%, 4.8%; 95% CI 2.3–8.7% in Ariana governorate and 0.3%; 95% CI 0.01%–1.8% in Manouba governorate. In multivariate analysis, the associated factors independently related to seroprevalence were age ≥25 years (aOR = 5.1; 95% CI 1.2–22.0), history of travel outside Tunisia since January 2020 (aOR = 4.6; 95% CI 1.7–12.9), symptomatic illness in the previous four months (aOR = 3.5; 95% CI 1.4–9.0) and governorate of residence (p = 0.02). The low seroprevalence estimated among household contacts in Great Tunis reflect the effect of public health measures early taken (national lockdown, borders closed, remote work), the respect of non-pharmaceutical interventions and the efficacy of COVID-19 contact-tracing and case management at the first stage of the pandemic in Tunisia. MDPI 2023-06-12 /pmc/articles/PMC10297112/ /pubmed/37367185 http://dx.doi.org/10.3390/epidemiologia4020020 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Dhaouadi, Sonia Letaief, Hejer Hechaichi, Aicha Safer, Mouna Moussa, Rym Bouhali, Ridha Letaief, Fethi Abdelkader, Latifa Ben Salah, Hamida El Mili, Nawel Hammami, Mongi Talmoudi, Khouloud Souteyrand, Yves Nabeth, Pierre Kouni Chahed, Mohamed Bouafif ép Ben Alaya, Nissaf Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia |
title | Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia |
title_full | Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia |
title_fullStr | Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia |
title_full_unstemmed | Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia |
title_short | Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia |
title_sort | baseline seroprevalence of sars-cov-2 specific antibodies in hot spot areas of great tunis, up to 3 months post disease onset in tunisia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297112/ https://www.ncbi.nlm.nih.gov/pubmed/37367185 http://dx.doi.org/10.3390/epidemiologia4020020 |
work_keys_str_mv | AT dhaouadisonia baselineseroprevalenceofsarscov2specificantibodiesinhotspotareasofgreattunisupto3monthspostdiseaseonsetintunisia AT letaiefhejer baselineseroprevalenceofsarscov2specificantibodiesinhotspotareasofgreattunisupto3monthspostdiseaseonsetintunisia AT hechaichiaicha baselineseroprevalenceofsarscov2specificantibodiesinhotspotareasofgreattunisupto3monthspostdiseaseonsetintunisia AT safermouna baselineseroprevalenceofsarscov2specificantibodiesinhotspotareasofgreattunisupto3monthspostdiseaseonsetintunisia AT moussarym baselineseroprevalenceofsarscov2specificantibodiesinhotspotareasofgreattunisupto3monthspostdiseaseonsetintunisia AT bouhaliridha baselineseroprevalenceofsarscov2specificantibodiesinhotspotareasofgreattunisupto3monthspostdiseaseonsetintunisia AT letaieffethi baselineseroprevalenceofsarscov2specificantibodiesinhotspotareasofgreattunisupto3monthspostdiseaseonsetintunisia AT abdelkaderlatifa baselineseroprevalenceofsarscov2specificantibodiesinhotspotareasofgreattunisupto3monthspostdiseaseonsetintunisia AT bensalahhamida baselineseroprevalenceofsarscov2specificantibodiesinhotspotareasofgreattunisupto3monthspostdiseaseonsetintunisia AT elmilinawel baselineseroprevalenceofsarscov2specificantibodiesinhotspotareasofgreattunisupto3monthspostdiseaseonsetintunisia AT hammamimongi baselineseroprevalenceofsarscov2specificantibodiesinhotspotareasofgreattunisupto3monthspostdiseaseonsetintunisia AT talmoudikhouloud baselineseroprevalenceofsarscov2specificantibodiesinhotspotareasofgreattunisupto3monthspostdiseaseonsetintunisia AT souteyrandyves baselineseroprevalenceofsarscov2specificantibodiesinhotspotareasofgreattunisupto3monthspostdiseaseonsetintunisia AT nabethpierre baselineseroprevalenceofsarscov2specificantibodiesinhotspotareasofgreattunisupto3monthspostdiseaseonsetintunisia AT kounichahedmohamed baselineseroprevalenceofsarscov2specificantibodiesinhotspotareasofgreattunisupto3monthspostdiseaseonsetintunisia AT bouafifepbenalayanissaf baselineseroprevalenceofsarscov2specificantibodiesinhotspotareasofgreattunisupto3monthspostdiseaseonsetintunisia |